Literature DB >> 22771186

Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.

Mark van der Linden1, Susanne Weiß, Gerhard Falkenhorst, Annette Siedler, Matthias Imöhl, Rüdiger von Kries.   

Abstract

INTRODUCTION: Vaccination with pneumococcal conjugate vaccine (PCV) for all children <2 years was recommended in Germany in July 2006. Initially PCV7 was exclusively used; PCV10 became available from April 2009 and PCV7 was replaced by PCV13 in December 2009.
OBJECTIVE: To compare the incidence and serotype distribution of invasive pneumococcal disease (IPD) for pneumococcal meningitis and non-meningitis IPD in children from 2007 to 2010 with reference to the pre-vaccination period from 1997 to 2001.
METHODS: Nationwide surveillance of IPD for children <16 years in Germany was based on two independent reporting sources: active surveillance in paediatric hospitals and passive web-based surveillance through microbiological laboratories. Serotyping was performed using the Neufeld Quellung reaction. CASE DEFINITION: isolation of Streptococcus pneumoniae from a normally sterile body site. IPD incidence was estimated by capture-recapture analysis. Rate ratios comparing post- to pre-vaccination incidence were calculated as well as PCV7 and non-PCV7 serotype specific incidences.
RESULTS: While PCV7 incidence decreased by 88% (95%CI: 83 to 91) in children <16 years both in pneumococcal meningitis and non-meningitis IPD, an increase in Non-PCV7 serotypes was observed which was more pronounced in non-meningitis cases (168%; 95%CI: 140-257) than in pneumoccocal meningitis (65%; 95%CI: 23-123). The changes in incidence after four years were: <16 years: -35% (95%CI: -49 to -19), <2 years: -46% (95%CI: -61 to -27) for pneumococcal meningitis and+11% (95%CI: -4 to +29) and -26% (95%CI: -41 to -7) for non-meningitis IPD respectively.
CONCLUSION: Infant PCV7 vaccination in Germany prompted a decrease in the incidence of pneumococcal meningitis similar to that observed in England/Wales. In non-meningitis IPD the decrease was smaller and confined to the age group <2 years with no change or an increase in incidence in other age groups pointing to potential ascertainment bias due to increased blood-culturing.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22771186     DOI: 10.1016/j.vaccine.2012.06.068

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  [Prevention in the elderly: position paper on pneumococcal vaccinations. Results of an expert workshop on 15 November 2013 in Cologne, Germany].

Authors:  G Fätkenheuer; A Kwetkat; M W Pletz; J Schelling; R-J Schulz; M van der Linden; T Welte
Journal:  Z Gerontol Geriatr       Date:  2014-06       Impact factor: 1.281

2.  Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.

Authors:  Alexander Kuhlmann; J-Matthias Graf von der Schulenburg
Journal:  Eur J Health Econ       Date:  2016-02-23

3.  Prevalence of Heptavalent Vaccine-related Pneumococcal Serotypes in Nasopharyngeal carrier in children under five years old in Shahrekord, Iran by Multiplex-PCR during 2010- 2011.

Authors:  Abolfazl Khoshdel; Reza Imani Rastabi; Abbas Doosti; Shahin Askari; Masoud Hafizi
Journal:  J Clin Diagn Res       Date:  2014-11-20

4.  The burden of pneumococcal meningitis in Austrian children between 2001 and 2008.

Authors:  D S Klobassa; B Zoehrer; M Paulke-Korinek; U Gruber-Sedlmayr; K Pfurtscheller; V Strenger; A Sonnleitner; R Kerbl; B Ausserer; W Arocker; W Kaulfersch; B Hausberger; B Covi; F Eitelberger; A Vécsei; B Simma; R Birnbacher; H Kurz; K Zwiauer; D Weghuber; S Heuberger; F Quehenberger; H Kollaritsch; W Zenz
Journal:  Eur J Pediatr       Date:  2014-01-14       Impact factor: 3.183

Review 5.  The Clinical Effectiveness of Pneumococcal Conjugate Vaccines: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Hannah Ewald; Matthias Briel; Danielle Vuichard; Veronika Kreutle; Andriy Zhydkov; Viktoria Gloy
Journal:  Dtsch Arztebl Int       Date:  2016-03-04       Impact factor: 5.594

6.  Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil.

Authors:  Juliana Caierão; Paulina Hawkins; Fernando Hayashi Sant'anna; Gabriela Rosa da Cunha; Pedro Alves d'Azevedo; Lesley McGee; Cícero Dias
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

7.  A retrospective analysis of hospital discharge records for S. pneumoniae diseases in the elderly population of Florence, Italy, 2010-2012.

Authors:  Angela Bechini; Cristina Taddei; Alessandro Barchielli; Miriam Levi; Emilia Tiscione; Maria Grazia Santini; Fabrizio Niccolini; Maria Teresa Mechi; Donatella Panatto; Daniela Amicizia; Chiara Azzari; Paolo Bonanni; Sara Boccalini
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  The febrile child: diagnosis and treatment.

Authors:  Tim Niehues
Journal:  Dtsch Arztebl Int       Date:  2013-11-08       Impact factor: 5.594

9.  Characteristics of invasive pneumococcal disease in hospitalized children in Austria.

Authors:  Maria Paulke-Korinek; Herwig Kollaritsch; Michael Kundi; Birgit Schmidle-Loss; Ines Zwazl; Brigitte Laaber; Karin Lakovits; Andreas Vecsei; Ursula Wiedermann; Heinz Burgmann
Journal:  Eur J Pediatr       Date:  2013-11-13       Impact factor: 3.183

10.  Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German children.

Authors:  Mark van der Linden; Ralf René Reinert; Winfried V Kern; Matthias Imöhl
Journal:  BMC Infect Dis       Date:  2013-02-05       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.